Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US
Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 (“pyrilutamide”) in the US for the treatment of male androgenetic alopecia (AGA) patients on February 28, 2022.
AGA is the most common type of hair loss affecting 50-60 million men and 30-35 million women in the US, but there are few therapeutic options. So, a safer and more effective drug is in urgent need to address the concerns for the people suffering from hair loss.
Dr. Youzhi Tong, founder, Chairman and CEO of Kintor Pharma, commented, ” As a topical AR antagonist, KX-826’s phase I and phase Ib clinical trials in the US have demonstrated a preliminary postive safety, pharmacokinetics and tolerability profile in dosing frequency. KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA male patients. We look forward to accelerating the clinical process of KX-826 and benefiting more people suffering from hair loss in China and globally.”
Source: Kintor Pharma